CSPC Pharmaceutical Advances Parkinson’s Treatment with New Clinical Trial Approval

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.

CSPC Pharmaceutical Group announced that its subsidiary, AlaMab Therapeutics Inc., has received approval to conduct a Phase II clinical trial in China for ALMB-0166, a novel treatment for Parkinson’s disease. This first-in-class humanized monoclonal antibody inhibitor targets the Connexin 43 protein to provide neuroprotection by inhibiting neuroinflammatory mediators. The approval marks a significant step in addressing the urgent need for innovative treatments in Parkinson’s disease, potentially improving patient outcomes and positioning CSPC as a leader in neurological disorder therapies.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong-based company engaged in the pharmaceutical industry, focusing on the development of innovative drugs. Its primary products include humanized monoclonal antibodies and other therapeutic drugs targeting neurological disorders.

YTD Price Performance: 119.37%

Average Trading Volume: 185,395,499

Technical Sentiment Signal: Buy

Current Market Cap: HK$119.1B

See more data about 1093 stock on TipRanks’ Stock Analysis page.